Ming Cai

Ming Cai


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 June 2025 in Renal Failure
Verified
Journal Article
Open access
LZLong Zheng
Long Zheng
WGWenjun Gao
Wenjun Gao
ZZZhenan Zhang
Zhenan Zhang
AHAn He
An He
QHQi Huangfu
Qi Huangfu
MCMing Cai
Ming Cai
Renal fibrosis is a common pathological endpoint of various chronic kidney diseases. Macrophages play an important role in the pathophysiological process of renal fibrosis. However, the exact function and molecular mechanism of macrophages during renal fibrosis remain unclear. In this study, we found an increased expression of RNA demethylase AlkB Homolog 5 (ALKBH5) in macrophages from the mice with unilateral ureteral obstruction (UUO) and TGF-β treatments bone marrow-derived macrophages. Macrophage-specific ALKBH5 knockout could significantly alleviate renal fibrosis in UUO mice and decrease the infiltration of macrophages in the kidneys. Further studies showed that ALKBH5 deficiency reduced M2a macrophage polarization and the expression of TGF-β1, Arg1, and CD206 both in vivo and in vitro. RNA sequencing indicated that Resistin-like alpha (Retnla) was the downstream target of ALKBH5, and treatment with recombinant Retnla abrogated the effect of ALKBH5 deficiency on renal fibrosis. We conclude that ALKBH5-dependent regulation of macrophage and kidney fibrosis progression through Retnla represents a novel strategy for patients with chronic kidney disease.

25 November 2023 in Life
Verified
Journal Article
Open access
PDF file
LXLiang Xu
Liang Xu
MCMing Cai
Ming Cai
Immune rejection is a significant concern in organ transplantation, as it can lead to damage to and failure of the transplanted organ. To prevent or treat immune rejection, transplant recipients are commonly administered immunosuppressive drugs. Tacrolimus (FK506) is a widely used immunosuppressive drug in organ transplantation. The excessive formation of neutrophil extracellular traps (NETs) can contribute to inflammation and tissue damage. Although NETs play an antimicrobial role, their overproduction can be harmful. To investigate the mechanism by which FK506 suppresses immune rejection, we utilized HL-60 cells, which were differentiated into neutrophils using DMSO and induced to form NETs with phorbol myristate acetate (PMA), a very efficient and frequently used drug for inducing NET formation. By comparing pre- and post-treatment with FK506, we examined whether FK506 affects the formation of NETs. Various experimental techniques were employed, including confocal imaging for visualizing cell NETs, qPCR and Western blotting for gene and protein expression analyses, ELISAs for protein content detection, and LC-MS/MS for methylation detection. In our study, we discovered that FK506 can enhance DNA methylation, which likely contributes to the reduction in NETs. Genes and proteins related to methylation, namely, DNMT3B and TET3, exhibited significant correlations with methylation. Consistent changes in both genes and proteins suggest that DNMT3B and TET3 are key factors that are influenced by FK506, resulting in enhanced DNA methylation and the potential inhibition of PMA-induced NET production. In summary, we have identified a novel mechanism by which FK506 inhibits NET production through the enhancement of DNA methylation. This finding highlights a new aspect of FK506′s immunosuppressive effect. Our results provide valuable insights for clinical research, immunosuppression, and organ preservation strategies.

21 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
CXCongcong Xu
Congcong Xu
QZQifeng Zhong
Qifeng Zhong
NYNengfeng Yu
Nengfeng Yu
XZXuqiang Zhang
Xuqiang Zhang
KYKefan Yang
Kefan Yang
YZYichun Zheng
Yichun Zheng
Background: Personalized anti-tumor therapy that activates the immune response has demonstrated clinical benefits in various cancers. However, its efficacy against testicular cancer (TC) remains uncertain. This study aims to identify suitable patients for anti-tumor immunotherapy and to uncover potential therapeutic targets in TC for the development of tailored anti-tumor immunotherapy. Methods: Consensus clustering analysis was conducted to delineate immune subtypes, while weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) regression, and support vector machine (SVM) algorithms were employed to evaluate the potential efficacy of anti-tumor immunotherapy. Candidate immunotherapy targets were systematically identified through multi-gene panel analyses and subsequently validated using molecular biology assays. A prioritized target emerging from cellular screening was further evaluated for its capacity to potentiate anti-tumor immunity. The therapeutic efficacy of this candidate was rigorously confirmed through a comprehensive suite of immunological experiments. Results: Following systematic screening of five candidate genes (WNT11, FAM181B, GRK5, FSCN1, and ECHS1), GRK5 emerged as a promising therapeutic target for immunotherapy based on its distinct functional and molecular associations with immune evasion mechanisms. Cellular functional assays revealed that GRK5 knockdown significantly attenuated the malignant phenotype of testicular cancer cells, as evidenced by reduced proliferative capacity and invasive potential. Complementary immunological validation established that specific targeting of GRK5 with the selective antagonist GRK5-IN-2 disrupts immune evasion pathways in testicular cancer, as quantified by T-cell-mediated cytotoxicity. Conclusions: These findings position GRK5 as a critical modulator of tumor-immune escape, warranting further preclinical exploration of GRK5-IN-2 as a candidate immunotherapeutic agent.

2 July 2026 in Acta Biomaterialia
Verified
Journal Article
Open access
JXJiaju Xu
Jiaju Xu
JXJinming Xu
Jinming Xu
YSYichang Shu
Yichang Shu
QHQi Huangfu
Qi Huangfu
LSLetian Shen
Letian Shen
JWJiaming Wen
Jiaming Wen
Clear cell renal cell carcinoma (ccRCC) remains a therapeutic challenge due to tyrosine kinase inhibitor (TKI) resistance and an immunosuppressive tumor microenvironment (TME). To avoid the limitations of systemic nanotherapeutics, which often suffer from inadequate tumor accumulation, we developed a pH-activatable injectable gelatin methacryloyl (GelMA) hydrogel (termed SUN/CuONPs@GelMA) for localized co-delivery of sunitinib and copper oxide nanoparticles. The photocrosslinkable GelMA matrix enables minimally invasive intratumoral administration and sustained drug retention. Unlike ferroptosis, which is frequently migigated by the antioxidant defenses inherent in ccRCC, cuproptosis circumvents this resistance by targeting mitochondrial metabolism. In the weakly acidic TME (pH 5.3-7), CuONP assemblies dissolve to release CuO nanoparticles and Cu2+, triggering dual mechanisms: (1) cuproptosis via mitochondrial proteotoxicity and the depletion of iron-sulfur cluster protein, and (2) Fenton-like reaction-mediated reactive oxygen species (ROS) generation and the release of damage-associated molecular patterns (DAMPs). Concurrently, sunitinib inhibits angiogenesis and synergizes with copper-driven immunomodulation to reprogram macrophages toward tumor-suppressive M1 phenotypes. In vitro and in vivo studies demonstrated potent tumor growth inhibition, migration suppression, and prolonged survival in ccRCC. The SUN/CuONPs@GelMA platform overcomes TKI resistance through the synergy of cuproptosis and immunotherapy. This localized co-delivery strategy provides a multi-mechanistic approach for the treatment of advanced ccRCC. STATEMENT OF SIGNIFICANCE: Systemic treatments for advanced clear cell renal cell carcinoma (ccRCC) are restricted by tyrosine kinase inhibitor (TKI) resistance, systemic toxicity, and an immunosuppressive tumor microenvironment (TME). We herein report a pH-activatable, injectable photocrosslinkable GelMA hydrogel for localized co-delivery of sunitinib and copper nanoparticles, enabling minimally invasive delivery, sustained drug retention, and reduced systemic toxicity. This hydrogel triggers cuproptosis via acidic TME-responsive copper release, and synergizes with sunitinib to reverse TKI resistance, suppress tumor progression and migration, reprogram immunosuppressive macrophages to antitumor phenotypes, and extend preclinical survival. This work establishes a combinatorial ccRCC therapeutic platform, providing a promising translational strategy for advanced ccRCC management.

20 March 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZZZhenan Zhang
Zhenan Zhang
MWMing Wang
Ming Wang
MCMing Cai
Ming Cai
Kidney transplantation is the optimal therapy for end-stage renal disease, yet long-term graft survival remains limited by ischemia-reperfusion injury, rejection, and chronic allograft dysfunction. Accumulating evidence indicates that multiple regulated cell death pathways-including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy-are critically involved in transplant injury. These pathways interact extensively, shaping the immune microenvironment, amplifying inflammation, and influencing graft fate. Emerging forms of cell death, such as cuproptosis, parthanatos, and NETosis, further expand the mechanistic landscape of transplant pathology. This review summarizes current mechanistic insights and experimental and clinical evidence linking regulated cell death to kidney transplant outcomes, and discusses therapeutic strategies targeting cell death pathways. Integrating cell death modulation into precision medicine may provide novel avenues to improve graft survival and patient prognosis.